Pharma News

The U.S. government announced on Friday that 15 medications, including Wegovy for weight loss and Ozempic for diabetes, will be part of the Medicare price negotiation plan set to take effect in 2027. This initiative stems from the Inflation Reduction Act

As the anticipated U.S. Biosecurity Act faces delays, much like the elusive Godot, industry participants are compelled to reevaluate the true role and value of CXOs in the biopharmaceutical landscape.

Recently, AstraZeneca announced that its BTK inhibitor, Calquence (acalbrutinib), has received FDA approval for a new indication. It is now authorized for use in combination with bendamustine and rituximab for the treatment of adult patients with previous

After a three-month hiatus, leading domestic anesthetics producer Humanwell Healthcare has officially been "acquired" by a state-backed entity. On January 15, the company announced that it had signed a restructuring investment agreement with Zhaoshang Inn

Today, January 15, Linda Wang, General Manager of Abbott Pharmaceuticals for China, announced a significant organizational change: the merger of the CPU and GI divisions into a new entity called the Gen Med Division. This restructuring aims to enhance ope

On January 7, 2025, Puli Pharmaceutical (stock code: ST Puli, 300630.SH) resumed trading after a suspension due to regulatory issues, immediately experiencing a 20% drop over three consecutive trading days. This decline followed the company's announcement

WuXi AppTec, a leading player in the ADC CDMO sector, has made bold projections for its performance in 2024. The CEO recently indicated that the company anticipates revenue, net profit, and adjusted net profit will grow by over 85%, 260%, and 170%, respec

Recently, the Lushui City People's Court publicly announced the verdict in a significant medical corruption case involving Chen and Miao. Chen was sentenced to four years in prison and fined 1.4 million yuan for multiple offenses, including utilizing infl

AstraZeneca has recently initiated a Phase III clinical trial for Rilvegostomig, a PD-1/TIGIT dual antibody, in a head-to-head comparison against Pembrolizumab (known as K drug) for treating non-squamous non-small cell lung cancer (NSCLC).

On January 14, shares of BeiGene (ONC.NS, 06160.HK, 688235.SH) saw an increase of over 9% in both A-shares and Hong Kong stocks, primarily driven by a favorable trend in the company's performance.

On January 13, Johnson & Johnson announced that it has reached a final agreement with biopharmaceutical company Intra-Cellular Therapies, which focuses on the development and commercialization of drugs for central nervous system (CNS) diseases.

On January 13, Xiansheng Pharmaceutical Group, through its subsidiary Xiansheng Zaiming, announced a collaboration agreement with AbbVie. According to the agreement, AbbVie will obtain licensing options for SIM0500 and will make an upfront payment as well

This marks the second disappointing performance for the company's stock since the drug was launched at the end of 2023. Eli Lilly's shares closed at $739.23, expected to record the largest single-day drop in nearly four years. Meanwhile, its Copenhagen-li

Johnson & Johnson announced on Monday that it will acquire the neuropharmaceutical manufacturer Intra-Cellular Therapeutics (ITCI.O) for $14.6 billion, significantly enhancing Johnson & Johnson's position in the brain disease treatment market and marking

Gilead Sciences and LEO Pharma recently announced a strategic partnership aimed at accelerating the development and commercialization of LEO Pharma's small molecule oral STAT6 (Signal Transducer and Activator of Transcription 6) inhibitors for potential i

On January 7, the People's Court of Longma Tan District, Luzhou City, Sichuan Province publicly tried a case of commercial bribery in the pharmaceutical field. Unlike previous cases, the defendant in this trial was the briber. This case originated from a

The U.S. Food and Drug Administration (FDA) has granted Johnson & Johnson fast track designation for its developing Tau monoclonal antibody Posdinemab for the treatment of early Alzheimer's disease (AD) patients. This decision was announced on January 8.

Eli Lilly China announced a significant personnel change on January 7, 2025. President and General Manager Huzur Devletsah informed all employees that Mr. Jiang Yifei, Vice President of the Neuroscience Division, has decided to leave the company to seek n

GEON Performance Solutions, a global leader in high-performance polymer material solutions formulation, development, and manufacturing, announced on January 7, 2025, the completion of its acquisition of Foster Corporation. Foster Corporation is renowned f

Puli Pharmaceuticals announced on January 5, 2025, that it is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws. The company received an "Administrative Penalty Notice" from th